Background: The most common autoimmune blistering disease, bullous pemphigoid (BP), shows an increased prevalence in psoriatic patients and oncologic patients undergoing immune-checkpoint blockade (ICB). Even though the same autoantigens (BP180/BP230) are detectable, it remains obscure whether clinical or histopathological differences exist between these different groups of BP patients. In this study, we strived to analyze this matter based on own data and previously published reports.

Methods: We performed an institutional chart review from 2010-2020 to identify BP patients with psoriasis ( = 6) or underlying ICB ( = 4) and matched them with idiopathic cases of BP ( = 33). We compared clinical characteristics, subtypes, and dermatopathological determinants (e.g., tissue eosinophilia/neutrophilia, papillary edema, lymphocytic infiltration) among the groups.

Results: ICB-associated BP affects men more often and might show mucosal involvement more frequently. We found no statistically significant dermatopathological differences among the groups.

Conclusions: Clinicians should be aware of an increased risk of BP in patients with psoriasis and oncologic patients receiving ICB; atypical pruritic skin lesions should prompt a workup including a skin biopsy for histopathology and direct immunofluorescence in these patients. Larger studies might be necessary to detect slight dermatopathological variation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947168PMC
http://dx.doi.org/10.3390/dermatopathology9010010DOI Listing

Publication Analysis

Top Keywords

bullous pemphigoid
8
patients
8
patients receiving
8
clinical histopathological
8
oncologic patients
8
patients psoriasis
8
pemphigoid patients
4
receiving immune-checkpoint
4
immune-checkpoint inhibitors
4
inhibitors psoriatic
4

Similar Publications

Macrophages in inflammatory skin diseases and skin tumors.

Front Immunol

December 2024

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Article Synopsis
  • - Macrophages are key immune cells that play diverse roles in the body, especially in the skin, which is the largest immune organ and is crucial for studying various skin-related conditions.
  • - This review focuses on recent findings about macrophages in inflammatory skin diseases like atopic dermatitis and psoriasis, as well as skin tumors such as melanoma and cutaneous T-cell lymphoma.
  • - The goal is to enhance understanding of how macrophages contribute to these diseases and explore potential new treatments targeting them.
View Article and Find Full Text PDF

We present the case of a 36-year-old paraplegic woman with a history of spinal cord injury who developed a generalized blistering rash, later diagnosed as bullous pemphigoid (BP). During her hospitalization, she was treated with prednisone and rituximab infusions, transitioning to maintenance therapy with topical steroids, doxycycline, and nicotinamide. A year later, she presented with concerns about a BP flare on her feet.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by enhancing the immune system's ability to target cancer cells. However, ICIs can lead to immune-related adverse events (irAEs), including dermatologic manifestations such as bullous pemphigoid (BP).

Objective: To evaluate the efficacy and safety of omalizumab and other biologics in the treatment of ICI-induced refractory bullous pemphigoid and to derive a strategy for selecting biologic treatments for this condition.

View Article and Find Full Text PDF

Background: Conventional systemic corticosteroid therapy for bullous pemphigoid (BP) has been challenged due to severe adverse events. Dupilumab has emerged as an alternative therapeutical option of BP patients.

Objectives: To evaluate the efficacy of dupilumab monotherapy and the combination with medium/low-dose corticosteroids for BP treatment.

View Article and Find Full Text PDF

Background: Robust and well-defined data collection is important when using electronic patient-reported outcome measures (ePROMs) in clinical studies. Questions have been raised as to whether older age may be a barrier to data collection due to patients' unfamiliarity with electronic devices. Older adults may also have underlying health conditions that affect their ability to fill out patient-reported outcome measures (PROMs) on electronic devices.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!